Abciximab Completed Phase 4 Trials for Shock, Cardiogenic Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT00420030Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock